Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities

References

• Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32(11):3225–3234.
   PubMed Web of Science ®Google Scholar
• Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14(2):1431–1437.
   PubMed Web of Science ®Google Scholar
• Takahashi R, Nakamura S, Nakazawa T, et al. Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase. J Biochem. 2010;147(1):95–107.
   PubMed Web of Science ®Google Scholar
• Martin PR, Shea RJ, Mulks MH. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol. 2001;183(4):1168–1174.
   PubMed Web of Science ®Google Scholar
• Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754–50763.
   PubMed Web of Science ®Google Scholar
• Dahl TB, Holm S, Aukrust P, et al. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr. 2012;32:229–243.
   PubMed Web of Science ®Google Scholar
• Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther. 2010;10(2):119–125.
   PubMed Web of Science ®Google Scholar
• Moore Z, Chakrabarti G, Luo X, et al. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone. Cell Death Dis. 2015;6:e1599.
   PubMed Web of Science ®Google Scholar
• Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464–471.
   PubMed Web of Science ®Google Scholar
• Burgos ES. NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism. Curr Med Chem. 2011;18(13):1947–1961.
   PubMed Web of Science ®Google Scholar
• Zhang T, Kraus WL. SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta. 2010;1804(8):1666–1675.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Greenberg RA. Deciphering the BRCA1 tumor suppressor network. J Biol Chem. 2015;290(29):17724–17732.
   PubMed Web of Science ®Google Scholar
• Hong EH, Yun HS, Kim J, et al. Nicotinamide phosphoribosyltransferase is essential for interleukin-1beta-mediated dedifferentiation of articular chondrocytes via SIRT1 and extracellular signal-regulated kinase (ERK) complex signaling. J Biol Chem. 2011;286(32):28619–28631.
   PubMed Web of Science ®Google Scholar
• Menssen A, Hydbring P, Kapelle K, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A. 2012;109(4):E187–E196.
   PubMed Web of Science ®Google Scholar
• Tao R, Wei D, Gao H, et al. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J Biol Chem. 2011;286(16):14681–14690.
   PubMed Web of Science ®Google Scholar
• Schuster S, Penke M, Gorski T, et al. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells. Biochem Biophys Res Commun. 2015;458:334–340.
   PubMed Web of Science ®Google Scholar
• Kauppinen A, Suuronen T, Ojala J, et al. Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal. 2013;25(10):1939–1948.
   PubMed Web of Science ®Google Scholar
• Adya R, Tan BK, Chen J, et al. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis. 2009;205(1):113–119.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Saglam M, Carrero JJ, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant. 2008;23(3):959–965.
   PubMed Web of Science ®Google Scholar
• Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78(2):356–365.
   PubMed Web of Science ®Google Scholar
• Ye SQ, Simon BA, Maloney JP, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med. 2005;171(4):361–370.
   PubMed Web of Science ®Google Scholar
• Zhou T, Wang T, Garcia JGN. Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers. Sci Rep. 2014;4:6107.
   PubMed Web of Science ®Google Scholar
• Soncini D, Caffa I, Zoppoli G, et al. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. J Biol Chem. 2014;289(49):34189–34204.
   PubMed Web of Science ®Google Scholar
• Santidrian AF, LeBoeuf SE, Wold ED, et al. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer. DNA Repair. 2014;23:79–87.
   PubMed Web of Science ®Google Scholar
• Bi TQ, Che XM, Liao XH, et al. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol Rep. 2011;26(5):1251–1257.
   PubMed Web of Science ®Google Scholar
• Audrito V, Serra S, Brusa D, et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood. 2015;125(1):111–123.
   PubMed Web of Science ®Google Scholar
• Ntikoudi E, Kiagia M, Boura P, et al. Hormones of adipose tissue and their biologic role in lung cancer. Cancer Treat Rev. 2014;40(1):22–30.
   PubMed Web of Science ®Google Scholar
• Kim HS, Han SY, Sung HY, et al. Blockade of visfatin induction by oleanolic acid via disturbing IL-6-TRAF6-NF-kappaB signaling of adipocytes. Exp Biol Med (Maywood, N.J.). 2014;239(3):284–292.
   PubMed Web of Science ®Google Scholar
• Romacho T, Villalobos LA, Cercas E, et al. Visfatin as a novel mediator released by inflamed human endothelial cells. Plos One. 2013;8(10):e78283.
   Google Scholar
• Romacho T, Sanchez-Ferrer CF, Peiro C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm. 2013;2013:946427.
   PubMed Web of Science ®Google Scholar
• Choi SH, Hong ES, Lim S. Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol. 2013;4:97.
   PubMedGoogle Scholar
• Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci. 2008;114(4):275–288.
   PubMed Web of Science ®Google Scholar
• Axelsson J, Stenvinkel P. Role of fat mass and adipokines in chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17(1):25–31.
   PubMed Web of Science ®Google Scholar
• Chini CCS, Guerrico AMG, Nin V, et al. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. Clin Cancer Res. 2014;20(1):120–130.
   PubMed Web of Science ®Google Scholar
• Khan JA, Forouhar F, Tao X, et al. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets. 2007;11(5):695–705.
   PubMed Web of Science ®Google Scholar
• Kulikova V, Shabalin K, Nerinovski K, et al. Generation, release, and uptake of the NAD precursor nicotinic acid riboside by human cells. J Biol Chem. 2015;290(45):27124–27137.
   PubMed Web of Science ®Google Scholar
• Shames DS, Elkins K, Walter K, et al. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors. Clin Cancer Res. 2013;19(24):6912–6923.
   PubMed Web of Science ®Google Scholar
• Garten A, Petzold S, Korner A, et al. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab. 2009;20(3):130–138.
   PubMed Web of Science ®Google Scholar
• Grozio A, Sociali G, Sturla L, et al. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. J Biol Chem. 2013;288(36):25938–25949.
   PubMed Web of Science ®Google Scholar
• Carneiro J, Duarte-Pereira S, Azevedo L, et al. The evolutionary portrait of metazoan NAD salvage. Plos One. 2013;8(5):e64674.
   Google Scholar
• Dalamaga M. Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges. Med Hypotheses. 2012;79(5):617–621.
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhou B, Zhang P, et al. Prognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer. Croat Med J. 2014;55(5):507–513.
   PubMed Web of Science ®Google Scholar
• Petelin A, Bizjak M, Cernelic-Bizjak M, et al. Low-grade inflammation in overweight and obese adults is affected by weight loss program. J Endocrinol Invest. 2014;37(8):745–755.
   PubMed Web of Science ®Google Scholar
• Shackelford RE, Bui MM, Coppola D, et al. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol. 2010;3(5):522–527.
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhou B, Zhang P, et al. Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group. Tumour Biol. 2014;35(5):4031–4040.
   PubMed Web of Science ®Google Scholar
• Aksoy P, White TA, Thompson M, et al. Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun. 2006;345(4):1386–1392.
   PubMed Web of Science ®Google Scholar
• Zhang T, Berrocal JG, Frizzell KM, et al. Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem. 2009;284(30):20408–20417.
   PubMed Web of Science ®Google Scholar
• Li D, Chen NN, Cao JM, et al. BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer. Cell Cycle. 2014;13(16):2564–2571.
   PubMed Web of Science ®Google Scholar
• Li D, Bi FF, Chen NN, et al. A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer. Cell Cycle. 2014;13(21):3442–3449.
   PubMed Web of Science ®Google Scholar
• Tan B, Young DA, Lu ZH, et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J Biol Chem. 2013;288(5):3500–3511.
   PubMed Web of Science ®Google Scholar
• Tolstikov V, Nikolayev A, Dong S, et al. Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells. Plos One. 2014;9(12):e114019.
   Google Scholar
• Sanokawa-Akakura R, Ostrakhovitch EA, Akakura S, et al. A H2S-Nampt dependent energetic circuit is critical to survival and cytoprotection from damage in cancer cells. PloS one. 2014;9(9):e108537.
   Google Scholar
• Ostrakhovitch EA, Akakura S, Sanokawa-Akakura R, et al. Dedifferentiation of cancer cells following recovery from a potentially lethal damage is mediated by H2S-Nampt. Exp Cell Res. 2015;330(1):135–150.
   PubMed Web of Science ®Google Scholar
• Cerna D, Li H, Flaherty S, et al. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner. J Biol Chem. 2012;287(26):22408–22417.
   PubMed Web of Science ®Google Scholar
• Zhu B, Deng X, Sun Y, et al. Nampt is involved in DNA double-strand break repair. Chin J Cancer. 2012;31(8):392–398.
   PubMed Web of Science ®Google Scholar
• Garten A, Schuster S, Penke M, et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol. 2015;11(9):535–546.
   PubMed Web of Science ®Google Scholar
• Thakur BK, Lippka Y, Dittrich T, et al. NAMPT pathway is involved in the FOXO3a-mediated regulation of GADD45A expression. Biochem Biophys Res Commun. 2012;420(4):714–720.
   PubMed Web of Science ®Google Scholar
• Wang B, Hasan MK, Alvarado E, et al. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene. 2011;30(8):907–921.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Thakur BK, Dittrich T, Chandra P, et al. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. Biochem Biophys Res Commun. 2012;424(3):371–377.
   PubMed Web of Science ®Google Scholar
• Thakur BK, Dittrich T, Chandra P, et al. Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells. Int J Cancer. 2013;132(4):766–774.
   PubMed Web of Science ®Google Scholar
• Gehrke I, Bouchard EDJ, Beiggi S, et al. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells. Clin Cancer Res. 2014;20(18):4861–4872.
   PubMed Web of Science ®Google Scholar
• Zoppoli G, Cea M, Soncini D, et al. Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp Hematol. 2010;38(11):979–988.
   PubMed Web of Science ®Google Scholar
• Hsu CP, Hariharan N, Alcendor RR, et al. Nicotinamide phosphoribosyltransferase regulates cell survival through autophagy in cardiomyocytes. Autophagy. 2009;5(8):1229–1231.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8(4):445–544.
   PubMed Web of Science ®Google Scholar
• Cea M, Cagnetta A, Fulciniti M, et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012;120(17):3519–3529.
   PubMed Web of Science ®Google Scholar
• Huang R, Xu Y, Wan W, et al. Deacetylation of nuclear LC3 drives autophagy initiation under starvation. Mol Cell. 2015;57(3):456–466.
   PubMed Web of Science ®Google Scholar
• van Horssen R, Willemse M, Haeger A, et al. Intracellular NAD(H) levels control motility and invasion of glioma cells. Cell Mol Life Sci. 2013;70(12):2175–2190.
   PubMed Web of Science ®Google Scholar
• Brentano F, Schorr O, Ospelt C, et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum. 2007;56(9):2829–2839.
   PubMed Web of Science ®Google Scholar
• Nowell M, Evans L, Williams A. PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis? Future Med Chem. 2012;4(6):751–769.
   PubMed Web of Science ®Google Scholar
• Meier FMP, Frommer KW, Peters MA, et al. Visfatin/pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing factor in rheumatoid arthritis. J Biol Chem. 2012;287(34):28378–28385.
   PubMed Web of Science ®Google Scholar
• Senolt L, Krystufkova O, Hulejova H, et al. The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine. 2011;55(1):116–121.
   PubMed Web of Science ®Google Scholar
• Goralski KB, Sinal CJ. Type 2 diabetes and cardiovascular disease: getting to the fat of the matter. Can J Physiol Pharmacol. 2007;85(1):113–132.
   PubMed Web of Science ®Google Scholar
• Paquot N, Tappy L. [Adipocytokines: link between obesity, type 2 diabetes and atherosclerosis]. Rev Med Liege. 2005;60(5–6):369–373.
   PubMedGoogle Scholar
• Arner P. Insulin resistance in type 2 diabetes – role of the adipokines. Curr Mol Med. 2005;5(3):333–339.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–1685.
   PubMed Web of Science ®Google Scholar
• Ognjanovic S, Jacobs DR, Steinberger J, et al. Relation of chemokines to BMI and insulin resistance at ages 18-21. Int J Obes. 2013;37(3):420–423.
   Web of Science ®Google Scholar
• Gorgian Mohammadi M, Hedayati M, Zarghami N, et al. Adipocyte derived hormones gene expression, resistin and visfatin, in AGS gastric cancer cell line. Iran J Cancer Prev. 2013;6(3):165–169.
   PubMedGoogle Scholar
• Wang P, Xu TY, Guan YF, et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81(2):370–380.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426–430.
   PubMed Web of Science ®Google Scholar
• Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49(4):744–747.
   PubMed Web of Science ®Google Scholar
• Garten A, Petzold S, Barnikol-Oettler A, et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun. 2010;391(1):376–381.
   PubMed Web of Science ®Google Scholar
• Gosset M, Berenbaum F, Salvat C, et al. Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum. 2008;58(5):1399–1409.
   PubMed Web of Science ®Google Scholar
• Friebe D, Neef M, Kratzsch J, et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 2011;54(5):1200–1211.
   PubMed Web of Science ®Google Scholar
• Pandzic Jaksic V. [Adipocytokines as mediators of metabolic role of adipose tissue]. Acta Med Croatica. 2010;64(4):253–262.
   PubMedGoogle Scholar
• Tanaka M, Nozaki M, Fukuhara A, et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun. 2007;359(2):194–201.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Gerner RR, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr Pharm Des. 2010;16(17):1913–1920.
   PubMed Web of Science ®Google Scholar
• Chen YY, Lai MH, Hung HY, et al. Sweet potato [Ipomoea batatas (L.) Lam. “Tainong 57”] starch improves insulin sensitivity in high-fructose diet-fed rats by ameliorating adipocytokine levels, pro-inflammatory status, and insulin signaling. J Nutr Sci Vitaminol. 2013;59(4):272–280.
   PubMed Web of Science ®Google Scholar
• Lebedeva T, Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol. 2005;17(3):251–258.
   PubMed Web of Science ®Google Scholar
• Lin YC, Wu HC, Liao CC, et al. Secretion of one adipokine Nampt/Visfatin suppresses the inflammatory stress-induced NF-kappaB activity and affects Nampt-dependent cell viability in Huh-7 cells. Mediators Inflamm. 2015;2015:392471.
   PubMedGoogle Scholar
• Romacho T, Azcutia V, Vazquez-Bella M, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 2009;52(11):2455–2463.
   PubMed Web of Science ®Google Scholar
• Boydens C, Maenhaut N, Pauwels B, et al. Adipose tissue as regulator of vascular tone. Curr Hypertens Rep. 2012;14(3):270–278.
   PubMed Web of Science ®Google Scholar
• Ray A, Alalem M, Ray BK. Insulin signaling network in cancer. Indian J Biochem Biophys. 2014;51(6):493–498.
   PubMed Web of Science ®Google Scholar
• Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174.
   PubMed Web of Science ®Google Scholar
• Gouranton E, Romier B, Marcotorchino J, et al. Visfatin is involved in TNFalpha-mediated insulin resistance via an NAD(+)/Sirt1/PTP1B pathway in 3T3-L1 adipocytes. Adipocyte. 2014;3(3):180–189.
   PubMedGoogle Scholar
• Pitoia F, Abelleira E, Bueno F, et al. Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer. Endocrine. 2015;48(3):894–901.
   PubMed Web of Science ®Google Scholar
• Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003;278(16):13740–13746.
   PubMed Web of Science ®Google Scholar
• I H, Cho JY. Lung cancer biomarkers. Adv Clin Chem. 2015;72:107–170.
   PubMedGoogle Scholar
• Bauer L, Venz S, Junker H, et al. Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1. Int J Oncol. 2009;35(1):97–107.
   PubMed Web of Science ®Google Scholar
• Long HL, Che XM, Bi TQ, et al. [The expression of nicotinamide phosphoribosyl transferase and vascular endothelial growth factor-A in gastric carcinoma and their clinical significance]. Zhonghua Wai Ke Za Zhi. 2012;50(9):839–842.
   PubMedGoogle Scholar
• Srivastava M, Khurana P, Sugadev R. Lung cancer signature biomarkers: tissue specific semantic similarity based clustering of digital differential display (DDD) data. BMC Res Notes. 2012;5:617.
   PubMedGoogle Scholar
• Shackelford R, Hirsh S, Henry K, et al. Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas. Anticancer Res. 2013;33(8):3047–3052.
   PubMed Web of Science ®Google Scholar
• Kiaii S, Clear AJ, Ramsay AG, et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol. 2013;31(21):2654–2661.
   PubMed Web of Science ®Google Scholar
• Maldi E, Travelli C, Caldarelli A, et al. Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions. Pigment Cell Melanoma Res. 2013;26(1):144–146.
   PubMed Web of Science ®Google Scholar
• Ni IB, Ching NC, Meng CK, et al. Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study. Hematol Rep. 2012;4(3):e19.
   Google Scholar
• Chan M, Gravel M, Bramoulle A, et al. Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption. Cancer Res. 2014;74(21):5948–5954.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Elkins K, Durieux JK, et al. Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618. Neoplasia. 2013;15(10):1151–1160.
   PubMed Web of Science ®Google Scholar
• Galli U, Travelli C, Massarotti A, et al. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J Med Chem. 2013;56(16):6279–6296.
   PubMed Web of Science ®Google Scholar
• Christensen MK, Erichsen KD, Olesen UH, et al. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship. J Med Chem. 2013;56(22):9071–9088.
   PubMed Web of Science ®Google Scholar
• Zheng X, Bauer P, Baumeister T, et al. Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. J Med Chem. 2013;56(16):6413–6433.
   PubMed Web of Science ®Google Scholar
• Oh A, Ho YC, Zak M, et al. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase. Chembiochem. 2014;15(8):1121–1130.
   PubMed Web of Science ®Google Scholar
• Jensen MM, Erichsen KD, Johnbeck CB, et al. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts. Plos One. 2013;8(1):e53410.
   Google Scholar
• Tan B, Lu Z, Dong S, et al. Derivatization of the tricarboxylic acid intermediates with O-benzylhydroxylamine for liquid chromatography-tandem mass spectrometry detection. Anal Biochem. 2014;465:134–147.
   PubMed Web of Science ®Google Scholar
• Wang W, Elkins K, Oh A, et al. Structural basis for resistance to diverse classes of NAMPT inhibitors. PloS one. 2014;9(10):e109366.
   Google Scholar
• Cagnetta A, Cea M, Calimeri T, et al. Intracellular NAD(+) depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013;122(7):1243–1255.
   PubMed Web of Science ®Google Scholar
• Bajrami I, Kigozi A, Van Weverwijk A, et al. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol Med. 2012;4(10):1087–1096.
   PubMed Web of Science ®Google Scholar
• Lee MW Jr., Sevryugina YV, Khan A, et al. Carboranes increase the potency of small molecule inhibitors of nicotinamide phosphoribosyltranferase. J Med Chem. 2012;55(16):7290–7294.
   PubMed Web of Science ®Google Scholar
• Yang HJ, Yen MC, Lin CC, et al. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity. Exp Biol Med. 2010;235(7):869–876.
   PubMed Web of Science ®Google Scholar